Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone.

Trial Profile

Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Neuroscience; Teva Pharmaceutical Industries
  • Most Recent Events

    • 14 Jun 2016 Time frame of primary end points has been changed from 17 years to 26 years.
    • 14 Jun 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
    • 14 Jun 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top